Alamar and Nightingale will hunt rare, low-level proteins in UK Biobank blood for signs of dementia and Parkinson’s long ...

Six-month University of Surrey RCT sees better endothelial function, less arterial stiffness and lower systolic pressure – ...

A Phase 1 study of MNA-001, which targets TREM2, saw age-linked markers in elderly volunteers shift toward levels seen in ...

Emory researchers say a 10-protein plasma signature outperformed the established marker, though it remains a research finding.

L-Nutra Health launches a clinician-led metabolic program in London, built on a patented plant-based diet designed to mimic ...

Why the next breakthroughs in healthy aging may come from the animal kingdom’s overlooked outliers, and from a rat with a genetic twist.

John Hancock and MIT AgeLab’s second index finds no change since 2025, with care the weakest area and community the strongest ...

Twelve abstracts head to The Liver Meeting, including a real-world comparison with resmetirom and four on investigational efruxifermin.

Latus Bio's Nature Communications paper models how lowering MSH3 could slow somatic instability – and buy years, perhaps decades.

Mission Therapeutics has begun a 36-patient Phase 1b study of MTX325, a drug aimed at clearing out damaged mitochondria in ...

Fractyl’s Revita hit its six-month goal in a sham-controlled pivotal trial, and the FDA filing is planned for late Q4 2026.

Swiss fertility heavyweight bets on stem-cell-derived egg maturation – and on ovarian biology as a market worth owning.